Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series

Hind RafeiDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Elias Joseph JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Kaylyn D. SinicropeDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Carlos Kamiya-MatsuokaDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Rohtesh S. MehtaDepartement of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Naval G. DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Tapan M. KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Kiran NaqviDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Jorge CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]

References